Search Results

Visterra antibody shows promise in preclinical study as universal flu vaccine

Cambridge, MA-based Visterra has unveiled positive preclinical data showing that its lead candidate VIS410, an engineered antibody, was effective at neutralizing strains of H5N1 and H7N9 influenza in mice. The study results show potential for a universal flu vaccine that could guard against seasonal ...

Delcath's chemo delivery device suffers FDA rejection

Systems' refuse-to-file letter Delcath's cancer drug delivery system hits FDA holdup ...

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

a rare-disease specialist, aims to change this in the near future. The Bedminster, NJ-based company plans to file ...

Synta gets FDA fast-track status for lung cancer drug; Bullet Biotechnology closes Series A;

| Follow @CarlyHFierce > Lilly files $500M lawsuit against Canada. News > Germany's Bayer joins ...

Diagnostics maker Foundation Medicine joins IPO flurry

FierceMedicalDevices | S-1 filing ...

Foundation Medicine eyes $92M in IPO

and clock a market value of $421 million. In its initial filing back in June, Foundation set its max ...

Smith & Nephew unveils wound dressing; Abbott issues another dividend;

weeks.  Report  | Follow  @CarlyHFierce > Lilly files $500M lawsuit against Canada.  News > ...

Visterra's engineered antibody passes preclinical test as universal flu treatment

Articles: Pandemic immune response hints at potential universal flu vaccine NIH makes progress on universal flu vaccine Gates Foundation backs $13M venture add for flu drug developer ...

Lilly files $500M lawsuit against Canada

The case was filed Thursday according to provisions of the North American Free Trade Agreement after ...

UPDATED: Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor Amarin

drug to a researcher in the U.S. ahead of filing the patent, putting no restrictions on how he used ...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »